Suchitra Sundaram, MD Suchitra Sundaram, MD

Suchitra Sundaram

MD
Hematologic Oncology

Specializing In:

Non Hodgkin Lymphoma Hodgkin Lymphoma Chronic Lymphocytic Leukemia Multiple Myeloma Benign Hematology

About Suchitra Sundaram

Biography:

Lymphoma is a complex set of diseases that can affect any organ system and I am drawn to the challenge of helping patients battle this challenging disease. Treating a serious illness like lymphoma needs a meticulous review of all aspects of the case, critical thinking, effective communication, while also providing the highest level of compassionate care for patients. While it's important to understand every detail of the disease, I also really focus on understanding the patient and their treatment goals to develop an individualized treatment plan that would improve their quality of life. I strive to ensure that my patients have access to cutting-edge novel therapies through clinical trials. Hence, apart from patient care, I am also involved in clinical research testing of new effective drug combinations in lymphoma.

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Lymphoma and Multiple Myeloma, Department of Medicine

Background

Education and Training:

  • MD - Lokmanya Tilak Medical College, Mumbai, India

Residency:

  • Cleveland Clinic Foundation, Cleveland, Ohio

Fellowship:

  • Case Western Reserve University, Cleveland, Ohio

Board Certification:

  • American Board of Internal Medicine

Professional Memberships:

  • American Society of Hematology
  • American Society of Clinical Oncology
  • Hemostasis and Thrombosis Research Society
  • American Medical Association

Honors & Awards:

  • American Society of Hematology Achievement Award
  • ASCO FDA Travel Grant
  • John W. Harris Memorial Travel Award
  • Sir Ratan Tata Scholarship for excellence in medicine

Clinical Trials


Publications

Full Publications list on PubMed
  • Sundaram S, Gravina M, Torka P, Attwood K, Hernandez-Ilizaliturri F Early Complete Remission by Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience (ASH 2019 Meeting abstract)
  • Sundaram S, Gravina M, Attwood K, Hernandez-Ilizaliturri, Torka P Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era (ASH 2019 Meeting abstract) Rhodes J, Sundaram S, Zayac A, Olszewski O, Caimi P, Braunstein Z, Brammer J, Waqas J, Umyarova E, Sheela S, Ghosh N, Nasta S, Barta S Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA) (ASH 2019 Meeting abstract)
  • Meyerson H., Sundaram S., Lazarus H.M. (2019) Bone Marrow Structure and Marrow Aspiration, Biopsy, and Collection for Therapeutic Intent Procedures. In: Lazarus H., Schmaier A. (eds) Concise Guide to Hematology. Springer, Cham Rhodes J, Sundaram S, Zayac A, Olszewski O, Caimi P, Braunstein Z, Brammer J, Waqas J, Umyarova E, Sheela S, Ghosh N, Nasta S, Barta S Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA) (ASH 2019 Meeting abstract)
  • Evens A, Danilov A, Jagadeesh D, Sperling A, Kim S, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Olszewski A Alderuccio J et al The Evaluation and Treatment of Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication across 26 US Cancer Centers (ASH 2019 Meeting abstract)
  • Zayac A, Evens A, Stadnik A, Smith S, Jagadeesh D, Leslie L, Wei C, Kim S, Naik S, Sundaram S, Reddy N, Farooq U, Olszewski A et al Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma and Central Nervous System Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis (ASH 2019 Meeting abstract)
  • Torka P, Reddy N, Groman A, Kader A, Nichols J, Hutson A, Mavis C, Tario J, Wallace P, Block A , Sait S, Baysal B, Neppalli V, Sundaram S, Hernandez-Ilizaliturri F Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study (ASH 2019 Meeting abstract)

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment